Is Codexis, Inc. (NASDAQ:CDXS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Codexis, Inc. at current levels.
The enzyme shop pivoting into RNAi manufacturing is being priced as a science project, not a picks-and-shovels play on the next drug wave.
Where CDXS is headed
By late 2027, the relevant question for Codexis isn't whether enzymes work for RNAi synthesis. It's whether ECO Synthesis becomes the default route for siRNA manufacturing as the modality breaks out of cardiometabolic into broader chronic disease. Novo's Rivfloza, Alnylam's Amvuttra in ATTR, and the pipeline behind them (zilebesiran, nedosiran, the cardiometabolic wave) all share one ugly secret. Solid-phase phosphoramidite chemistry, the current manufacturing route, was designed for milligram research quantities, not tonne-scale chronic dosing. The cost curve does not bend. The waste streams are brutal. Codexis is selling the alternative.
Read the full Compass Direction on CDXS
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $2.57).
See the full CDXS analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Codexis, Inc. (NASDAQ:CDXS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Codexis, Inc. at current levels. The enzyme shop pivoting into RNAi manufacturing is being priced as a science project, not a picks-and-shovels play on the next drug wave.
What is CDXS's Compass Score?
Codexis, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for CDXS?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the CDXS page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.